1. Home
  2. SRPT
  3. SRPT News

Latest Sarepta Therapeutics Inc. (DE) (SRPT) News on December 18, 2024

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
SRPT

Business Wire

8 hours ago

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
SRPT

Zacks

a day ago

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025

SRPT

MT Newswires

2 days ago

Sarepta Therapeutics Insider Sold Shares Worth $1,310,820, According to a Recent SEC Filing

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
SRPT

Insider Monkey

4 days ago

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
SRPT

Zacks

5 days ago

Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?

SRPT

Argus Research

8 days ago

SRPT: What does Argus have to say about SRPT?

Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?
SRPT

Zacks

12 days ago

Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?

SRPT

Argus Research

15 days ago

SRPT: Lowering target price to $101.00

SRPT

Zacks Small Cap Research

15 days ago

ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…

Arrowhead price target lowered to $24 from $27 at Bernstein
SRPT

TipRanks

18 days ago

Arrowhead price target lowered to $24 from $27 at Bernstein

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT

Business Wire

19 days ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
SRPT

Zacks

19 days ago

Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?

Sarepta price target lowered to $202 from $205 at Needham
SRPT

TipRanks

20 days ago

Sarepta price target lowered to $202 from $205 at Needham

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
SRPT

Zacks

21 days ago

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies

Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet
SRPT

Zacks

21 days ago

Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet

Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments
SRPT

TipRanks

21 days ago

Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments

Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board
SRPT

TipRanks

21 days ago

Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board

Sarepta rebuilds drug pipeline with Arrowhead deal
SRPT

BioPharma Dive

21 days ago

Sarepta rebuilds drug pipeline with Arrowhead deal

Arrowhead and Sarepta link for rare genetic disease treatments
SRPT

Pharmaceutical Technology

21 days ago

Arrowhead and Sarepta link for rare genetic disease treatments

SRPT

Argus Research

22 days ago

SRPT: Raising target price to $104.00

Arrowhead Pharma, Sarepta TX ink new gene therapy deal
SRPT

Yahoo Finance Video

22 days ago

Arrowhead Pharma, Sarepta TX ink new gene therapy deal

SRPT

MT Newswires

22 days ago

Sector Update: Health Care

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
SRPT

Investor's Business Daily

22 days ago

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta
SRPT

Investor's Business Daily

22 days ago

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta

SRPT

MT Newswires

22 days ago

Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
SRPT

Business Wire

22 days ago

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

High Growth Tech Stocks to Watch in November 2024
SRPT

Simply Wall St.

a month ago

High Growth Tech Stocks to Watch in November 2024

Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now
SRPT

Insider Monkey

a month ago

Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now

Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem
SRPT

Simply Wall St.

a month ago

Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem

SRPT

Argus Research

a month ago

SRPT: Lowering target price to $91.00

Sarepta recent weakness brings buying opportunity, says JPMorgan
SRPT

TipRanks

a month ago

Sarepta recent weakness brings buying opportunity, says JPMorgan

Sarepta price target lowered to $193 from $200 at Baird
SRPT

TipRanks

a month ago

Sarepta price target lowered to $193 from $200 at Baird

SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
SRPT

Zacks

a month ago

SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program

SRPT

MT Newswires

a month ago

Cantor Fitzgerald Upgrades Sarepta Therapeutics to Overweight, $167 Price Target

Sarepta scraps a Duchenne drug as gene therapy sales rise
SRPT

BioPharma Dive

a month ago

Sarepta scraps a Duchenne drug as gene therapy sales rise

SRPT

MT Newswires

a month ago

Sarepta Therapeutics Q3 Adjusted Earnings, Revenue Rise

Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
SRPT

Motley Fool

a month ago

Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript

Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
SRPT

GuruFocus.com

a month ago

Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
SRPT

Zacks

a month ago

Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

SRPT

Associated Press Finance

a month ago

Sarepta Therapeutics: Q3 Earnings Snapshot

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
SRPT

Business Wire

a month ago

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments

SRPT

Argus Research

a month ago

SRPT: Lowering target price to $100.00

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT

Business Wire

2 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (SRPT): An Unstoppable Stock That Could Make You Richer
SRPT

Insider Monkey

2 months ago

Sarepta Therapeutics, Inc. (SRPT): An Unstoppable Stock That Could Make You Richer

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
SRPT

Business Wire

2 months ago

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

Exploring High Growth Tech Stocks In United States October 2024
SRPT

Simply Wall St.

2 months ago

Exploring High Growth Tech Stocks In United States October 2024

SRPT

MT Newswires

2 months ago

Jefferies Initiates Sarepta Therapeutics at Buy With $165 Price Target

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
SRPT

Investor's Business Daily

2 months ago

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

2 High-Flying Growth Stocks With Massive Upside Potential
SRPT

Motley Fool

2 months ago

2 High-Flying Growth Stocks With Massive Upside Potential

Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds?
SRPT

Insider Monkey

2 months ago

Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds?

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $96.00

SRPT

MT Newswires

2 months ago

RBC Lifts Price Target on Sarepta Therapeutics to $182 From $181, Keeps Outperform Rating

Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
SRPT

Motley Fool

3 months ago

Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT

Business Wire

3 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts?
SRPT

Insider Monkey

3 months ago

Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts?

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
SRPT

Business Wire

3 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress

Exploring TeraWulf And Two Other High Growth Tech Stocks
SRPT

Simply Wall St.

3 months ago

Exploring TeraWulf And Two Other High Growth Tech Stocks

Sarepta Therapeutics (SRPT): Soaring with Successful Therapies and Cash Flow Positivity
SRPT

Insider Monkey

3 months ago

Sarepta Therapeutics (SRPT): Soaring with Successful Therapies and Cash Flow Positivity

Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
SRPT

Zacks

3 months ago

Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
SRPT

Business Wire

3 months ago

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

Sarepta Therapeutics, Inc. (SRPT): Among Hedge Funds’ Top Biotech Stock Picks
SRPT

Insider Monkey

3 months ago

Sarepta Therapeutics, Inc. (SRPT): Among Hedge Funds’ Top Biotech Stock Picks

These 2 Biotech Stocks Are Set to Soar
SRPT

Motley Fool

3 months ago

These 2 Biotech Stocks Are Set to Soar

Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar
SRPT

Insider Monkey

3 months ago

Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar

Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
SRPT

Zacks

3 months ago

Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?

Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
SRPT

Business Wire

3 months ago

Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
SRPT

Benzinga

3 months ago

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT

Business Wire

4 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DMD clinical studies evolve with emphasis on building designs around relevant endpoints
SRPT

Clinical Trials Arena

4 months ago

DMD clinical studies evolve with emphasis on building designs around relevant endpoints

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
SRPT

Business Wire

4 months ago

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

SRPT

Argus Research

4 months ago

SRPT: Raising target price to $113.00

High Growth Tech Stocks To Watch In August 2024
SRPT

Simply Wall St.

4 months ago

High Growth Tech Stocks To Watch In August 2024

SRPT

Argus Research

4 months ago

SRPT: Raising target price to $112.00

Heard Writers Pick Their Favorite and Least-Favorite Stocks
SRPT

The Wall Street Journal

4 months ago

Heard Writers Pick Their Favorite and Least-Favorite Stocks

SRPT

MT Newswires

4 months ago

Sarepta Therapeutics Insider Bought Shares Worth $4,955,728, According to a Recent SEC Filing

Bull Signal Flashing for Sarepta Therapeutics Stock
SRPT

Schaeffer's Investment Research

4 months ago

Bull Signal Flashing for Sarepta Therapeutics Stock

A $3 Million Gene-Therapy Maker at a Bargain Price
SRPT

The Wall Street Journal

4 months ago

A $3 Million Gene-Therapy Maker at a Bargain Price

Shareholders In Sarepta Therapeutics (NASDAQ:SRPT) Should Look Beyond Earnings For The Full Story
SRPT

Simply Wall St.

4 months ago

Shareholders In Sarepta Therapeutics (NASDAQ:SRPT) Should Look Beyond Earnings For The Full Story

2 Biotech Stocks to Buy Hand Over Fist in August
SRPT

Motley Fool

4 months ago

2 Biotech Stocks to Buy Hand Over Fist in August

Some Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Analysts Just Made A Major Cut To Next Year's Estimates
SRPT

Simply Wall St.

4 months ago

Some Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Analysts Just Made A Major Cut To Next Year's Estimates

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
SRPT

Investor's Business Daily

4 months ago

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics

SRPT

MT Newswires

4 months ago

UBS Raises Sarepta Therapeutics Price Target to $188 From $173, Maintains Buy Rating

Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)
SRPT

Zacks

4 months ago

Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)

Can Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Improve Its Returns?
SRPT

Simply Wall St.

4 months ago

Can Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Improve Its Returns?

SRPT

Thomson Reuters StreetEvents

4 months ago

Q2 2024 Sarepta Therapeutics Inc Earnings Call

SRPT

MT Newswires

4 months ago

Evercore ISI Upgrades Sarepta Therapeutics to Outperform From In Line, Adjusts Price Target to $179 From $185

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
SRPT

Zacks

4 months ago

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak

Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
SRPT

Motley Fool

4 months ago

Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
SRPT

Zacks

4 months ago

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

SRPT

Investing.com

4 months ago

Sarepta Therapeutics falls on revenue miss, weak outlook

SRPT

MT Newswires

4 months ago

Sarepta Therapeutics Swings to Q2 Non-GAAP Earnings; Revenue Rises

SRPT

Associated Press Finance

4 months ago

Sarepta Therapeutics: Q2 Earnings Snapshot

Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
SRPT

Business Wire

4 months ago

Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments

What Makes Sarepta Therapeutics (SRPT) a New Buy Stock
SRPT

Zacks

4 months ago

What Makes Sarepta Therapeutics (SRPT) a New Buy Stock

Sarepta Therapeutics (NASDAQ:SRPT) A Bull Case Theory
SRPT

Insider Monkey

5 months ago

Sarepta Therapeutics (NASDAQ:SRPT) A Bull Case Theory

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT

Business Wire

5 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
SRPT

Zacks

5 months ago

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics

SRPT

MT Newswires

5 months ago

Sarepta Therapeutics Poised for 'Significant Launch Inflection' Amid Positive Elevidys Feedback, RBC Says

5 Biotech Stocks to Bet On Bright Industry Prospects
SRPT

Zacks

5 months ago

5 Biotech Stocks to Bet On Bright Industry Prospects

Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
SRPT

Business Wire

5 months ago

Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results

SRPT

MT Newswires

5 months ago

RBC Upgrades Sarepta Therapeutics to Outperform From Sector Perform, Keeps Price Target at $182

Share on Social Networks: